A biotech that closes a Series B has just been handed money with a mandate attached: move the lead program forward, fast. Within roughly a quarter, they will have chosen a CRO. The only question is whether you were in that conversation.
Why the funding round is the loudest signal you get
Most buying signals require interpretation. A funding round does not. It tells you, publicly and precisely, that a company now has capital, a stated plan for spending it, and internal pressure to show progress before the next raise.
For a CRO, this is as close to a purchase intent notification as this industry produces. The company said what the money is for. It is usually a trial.
The window is roughly 90 days
This is the part that costs CROs money. The window does not stay open.
A company that raises in January is scoping vendors in February and selecting in March. By the time you notice the round in a quarterly review, or hear about it at a conference, the decision has been made and you were never in it. Nobody tells you. You simply never hear from them, and you assume they were not in the market.
They were in the market. You were late.
How to read the round properly
- The stated use of proceeds is the most underread sentence in the press release. “To advance BMN-101 into Phase 2” is a trial that needs running, on a known timeline.
- The size tells you the scale of the program and roughly what they can afford.
- The stage tells you the trial type. A Series A is likely first-in-human. A crossover round often means a registrational program is coming.
- The therapeutic area tells you whether it is you they need, or someone else.
What to actually say
Not “congratulations, let us know if you need anything.” That is a cold email with confetti on it.
Say something that proves you understand their program: that you have run trials in their indication, that you know what the operational challenge will be for a study like theirs, that you have a view on the enrollment problem they are about to discover. You are not asking for a meeting. You are demonstrating that you already understand their problem, which is the only thing that earns you one.
Know who to call
Somewhere this week, a biotech in your therapeutic area closed a round and started scoping trial partners. Ninety days from now, that decision is made.
Get Signals for your BD team, $8,000/year for up to 5 seats
Or a single seat, $2,500/year
Every Friday: 15 to 20 tagged signals, a “Who To Call This Week” list of 10 prioritized targets with the trigger and a suggested opening line, and a monthly outreach playbook. Two-week free trial, no commitment. See also the buying signals biotech vendors keep missing.
Frequently asked questions
Why are funding rounds a buying signal for CROs?
Because a biotech that raises has capital, a stated plan for spending it, and pressure to show progress before the next round. The press release usually names the program the money will advance, which is typically a trial that needs running. It is the closest thing to a purchase intent notification this industry produces.
How quickly do biotechs choose a CRO after funding?
Typically within a quarter. A company that raises in January is often scoping vendors in February and selecting in March. CROs who notice the round in a quarterly review or hear about it at a conference are usually too late, and they never find out, because nobody tells you that a shortlist was built without you.
What should a CRO say after a biotech raises?
Not congratulations. Demonstrate that you understand their program: that you have run trials in their indication, that you know the operational challenges a study like theirs will face, and that you have a view on the enrollment problem they are about to encounter. Understanding their problem is what earns the meeting.
